[{"id":"50ea29fe-c7d0-4fe7-8f3c-79d7d1f246bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01064713","created_at":"2021-01-18T04:11:42.378Z","updated_at":"2024-07-02T16:37:08.918Z","phase":"Phase 2","brief_title":"Phase II Study of Tesetaxel in Metastatic Melanoma","source_id_and_acronym":"NCT01064713","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tesetaxel (DJ 927)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 02/01/2010","start_date":" 02/01/2010","primary_txt":" Primary completion: 10/01/2014","primary_completion_date":" 10/01/2014","study_txt":" Completion: 10/01/2014","study_completion_date":" 10/01/2014","last_update_posted":"2018-07-17"}]